Background: cost of anticoagulation with dabigatran is largely based on estimation of
complication rates derived from clinical trials. Objective: to investigate cost of anticoagulation …

Background To compare the management cost and cost‐effectiveness of dabigatran with
warfarin in patients with nonvalvular atrial fibrillation (AF) from the hospital's and patients' …

Objectives The introduction of new oral anticoagulants for the prevention of stroke in atrial
fibrillation (AF) has changed the clinical management of AF. To inform decision making …

Abstract Introduction and Objectives To estimate the cost-effectiveness and cost-utility of
dabigatran in the prevention of stroke and systemic embolism in patients with non-valvular …

Background—Recent studies have investigated alternatives to warfarin for stroke
prophylaxis in patients with atrial fibrillation (AF), but whether these alternatives are cost …

The RE-LY study demonstrated the safety and efficacy of dabigatran relative to warfarin for
stroke prevention in non-valvular atrial fibrillation. It is important to further evaluate safety …

Background: Warfarin reduces the risk for ischemic stroke in patients with atrial fibrillation
(AF) but increases the risk for hemorrhage. Dabigatran is a fixed-dose, oral direct thrombin …

Background: Warfarin has provided protection against cardioembolic stroke in the setting of
nonvalvular atrial fibrillation (NVAF) for the past 60 years. Dabigatran, the first oral direct …

Background New antithrombotic drugs for prevention and treatment of thromboembolic
disorders in AF that are less demanding on local staff and facilities than warfarin should be …

Objectives: Atrial fibrillation is a major risk factor for ischemic stroke and anticoagulation
therapy is indicated to reduce risk. Dabigatran is a new oral anticoagulant that does not …